Ironwood Acquires VectivBio, a Clinical-Stage Biotech Company Developing Novel Treatments for Severe Rare Gastrointestinal Diseases

Ironwood Pharmaceuticals, a leading gastrointestinal (GI) healthcare company, has recently announced its definitive agreement to acquire VectivBio, a clinical-stage biotech company focused on developing innovative treatments for severe, rare gastrointestinal diseases. This strategic transaction marks a significant milestone for Ironwood as it advances its vision of becoming the foremost player in the GI healthcare sector.

Established in Cambridge, Ironwood Pharmaceuticals operates as a biotechnology firm. Ironwood is committed to the research, development, and commercialization of novel therapeutics for the treatment of gastrointestinal and other diseases. Developing new medicines by combining the company's knowledge of biology, chemistry, and pharmacology is a top priority. 

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Ironwood's commitment to addressing unmet medical needs in the GI field is exemplified by its addition of apraglutide, a next-generation synthetic GLP-2 analog, to its portfolio.

Apraglutide is currently in Phase 3 clinical trials for the treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF), a condition characterized by the inability to absorb sufficient nutrients due to a shortened or dysfunctional small intestine. Ironwood's potential Best-in-class therapy aims to improve the quality of life for patients suffering from SBS-IF.

In recognition of the urgent need for effective treatments for SBS-IF, apraglutide has received Orphan Drug Designation. This designation signifies the significance and potential impact of the therapy for the treatment of adult patients with SBS-IF. Ironwood expects to announce topline results from the Phase 3 trial by the end of 2023, bringing hope to those affected by this debilitating condition.

As part of its strategic expansion, Ironwood intends to initiate an all-cash tender offer to acquire all outstanding shares of VectivBio for $17.00 per share. VectivBio, a clinical-stage biotech company, has also earned recognition for its dedication to developing novel therapies for severe, rare gastrointestinal diseases.

By acquiring VectivBio, Ironwood strengthens its position in the GI healthcare sector, leveraging the scientific expertise and pipeline of innovative treatments of its new partner. The acquisition of VectivBio is a testament to Ironwood's commitment to driving innovation and addressing unmet medical needs in the GI field.